AbCellera Biologics Inc. (ABCL)
Nasdaq · Healthcare · Biotechnology
$13.78+0.29%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $4.5B
- 52-week range
- $2.75 – $15.02
- 52-week change
- +138.13%
- EPS (trailing)
- −$0.54
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $75.1M (+160.56%)
- Net income
- −$146M
- Operating margin
- −289.0%
- Diluted EPS
- −$0.49
- Free cash flow
- −$174M
From the company’s annual report on SEC EDGAR.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Headquarters: Vancouver, Canada · 562 employees · abcellera.com